-
Mashup Score: 0Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma - 3 day(s) ago
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer - 3 day(s) ago
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer. Learn more: https://t.co/dMiQM54Vgo #medtwitter #onctwitter https://t.co/7v86ceUBUQ
-
-
Mashup Score: 0Advancements in Treatment Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma - 4 day(s) ago
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory #DLBCL including bispecific #antibodies and CAR T-cell therapy. Learn more: https://t.co/jUnbRapu4g https://t.co/7dfHI22Qxs
-
-
Mashup Score: 0First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer - 4 day(s) ago
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to final efficacy and safety results from the phase 3b #LUMINANCE trial, first-line #durvalumab plus platinum-#etoposide demonstrated promise among patients with extensive-stage #SCLC. Learn more: https://t.co/yrJjlWO9tr #medtwitter #onctwitter https://t.co/tLtjLnJ8Um
-
-
Mashup Score: 0Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma - 5 day(s) ago
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
The presence of 2 or more high-risk cytogenetic #abnormalities among patients with #MM was associated with poor survival outcomes, according to a systematic review and meta-analysis. Learn more: https://t.co/CN4eWKyeIT https://t.co/WchmXcpjM1
-
-
Mashup Score: 0
Alison Schram, MD, discusses the results from the eNRGy trial, evaluating the bispecific antibody against HER2 and HER3, zenocutuzumab for patients with NRG1 fusion-positive cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Alison Schram, MD, discusses data from the phase 2 #eNRGy study which evaluated #zenocutuzumab among patients with #NRG1 fusion-positive cancer of any tumor type. Learn more: https://t.co/BAcHFBM239 #medtwitter #onctwitter https://t.co/6IulbnUYCF
-
-
Mashup Score: 0
In part 2 of this expert roundtable covering the latest updates in myelofibrosis treatment and management, Firas El Chaer, MD, discusses their strategies and process for selecting best first-line therapy with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
In part 2 of this expert #roundtable covering updates in #myelofibrosis treatment and management, Firas El Chaer, MD, discusses their strategies for selecting optimal frontline therapy with Raajit K Rampal, MD, and Lindsay A M Rein, MD. Learn more: https://t.co/ATm84gyKzL https://t.co/LzQqn9UCBk
-
-
Mashup Score: 0Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma - 6 day(s) ago
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the phase 3 #ILLUMINATE301 study, the addition of #tilsotolimod to #ipilimumab did not significantly improve outcomes among patients with unresectable, advanced refractory melanoma. Learn more: https://t.co/hunnznbvRp #medtwitter #onctwitter https://t.co/Xe32FEbd7k
-
-
Mashup Score: 0
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Treatment for relapsed/refractory #DLBCL with #odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy. Learn more: https://t.co/hLfo1Za1ik https://t.co/Zs4K6wik5S
-
-
Mashup Score: 0First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50% - 7 day(s) ago
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line #cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced #NSCLC with PD-L1 ≥ 50%. Learn more: https://t.co/yyybYoUi1O #medtwitter #onctwitter https://t.co/9N4WPx9vpH
-
Quadruplet therapy with #isatuximab, weekly bortezomib, lenalidomide, and limited #dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible #MM in a phase 2 clinical trial. Learn more: https://t.co/oAcmudqowA https://t.co/CMkAm1Mvif